• The D'Andrea study, performed on 53 patients receiving therapy for cancer, showed that Gelclair^® is an effective intervention in terms of improvements in pain, functionality, and grade of mucositis.  

• Gelclair^® can reduce 1 grade of the grade of mucositis after only 3 days of treatment. 
• Gelclair^® improves patients' quality of life reducing the difficulty in eating and drinking.

Reference:
D'Andrea et al, Annals of Oncology 2003; 14 (suppl. 4):97 (abs 2).